BiotechTube

ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal Placebo

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Herpes Zoster

Conditions

Herpes Zoster

Trial Timeline

Sep 1, 2011 → May 1, 2013

NCT ID
NCT01385566

About ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal Placebo

ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) 1/3 Dose Subcutaneous + ZOSTAVAX™ (Zoster Vaccine Live) Full Dose Intradermal + ZOSTAVAX™ (Zoster Vaccine Live) Partial Doses Intradermal + Full Dose Intradermal Placebo + Intradermal Placebo is a phase 1 stage product being developed by Merck for Herpes Zoster. The current trial status is completed. This product is registered under clinical trial identifier NCT01385566. Target conditions include Herpes Zoster.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01385566Phase 1Completed

Competing Products

20 competing products in Herpes Zoster

See all competitors
ProductCompanyStageHype Score
ASP2151 + Valacyclovir hydrochlorideAstellas PharmaPhase 2
52
ASP2151 + PlaceboAstellas PharmaPhase 1
33
ASP2151 + valacyclovir + PlaceboAstellas PharmaPhase 2
52
Dolutegravir 50 mg tablet + Dolutegravir 50 mg oral granulesShionogiPhase 1
33
GSK1349572 + EfavirenzShionogiPhase 1
33
Zoster Vaccine, Live + Comparator: PlaceboMerckPhase 2
52
Comparator: V212 + Comparator: PlaceboMerckPhase 1
33
Zoster Vaccine, LiveMerckPhase 3
77
V212 + PlaceboMerckPhase 3
77
zoster vaccine live (ZOSTAVAX™) + Comparator: PlaceboMerckPhase 3
77
ZOSTAVAXMerckPhase 3
77
Zoster Vaccine, Live (AMP) + Zoster Vaccine, LiveMerckPhase 3
77
V212 + PlaceboMerckPhase 2
52
V212 + Matching placeboMerckPhase 3
77
V212 Lot 1 + V212 Lot 2 + V212 Lot 3MerckPhase 3
77
HSV 2 Formulation 1 + HSV 2 Formulation 2 + HSV 2 Formulation 3 + HSV 2 Formulation 4 + HSV 2 Formulation 5 + HSV 2 Formulation 6 + Sodium Chloride 0.9%MerckPhase 1
33
V212 + PlaceboMerckPhase 1
33
Zoster Vaccine, Live, (Oka-Merck), ZOSTAVAX™ + Comparator: placebo (concomitant-vaccine matched) + Pneumococcal Vaccine, Polyvalent (23-valent), PNEUMOVAX™ 23MerckPhase 3
77
ZOSTAVAX™ (concomitant) + Comparator: Influenza Vaccine + ZOSTAVAX™ (Nonconcomitant)MerckPhase 3
77
ZOSTAVAX™MerckPre-clinical
23

Other Products from Merck

DuleraApproved
85
ImipenemApproved
85
Mavenclad®Approved
85
raltegravir + PlaceboApproved
85
alendronate sodiumApproved
85